Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 13/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288262 | 0.88 | FFAR1 (0.39) | CPS1HCRTR1HCRTR2FFAR1PPARD | |
| SCHEMBL4293913 | 0.88 | DRD3 (0.45) | HCRTR1HCRTR2KDM4E | |
| SCHEMBL4284003 | 0.87 | HCRTR1 (0.41) | HCRTR1HCRTR2KDM4E | |
| SCHEMBL4281669 | 0.86 | KDM4E (0.39) | CPS1HCRTR1HCRTR2KDM4E | |
| SCHEMBL4290602 | 0.86 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM4ELMNA | |
| SCHEMBL4290115 | 0.85 | ALDH1A1 (0.45) | HCRTR1HCRTR2KDM4ELMNA | |
| SCHEMBL4286355 | 0.85 | HCRTR1 (0.44) | CPS1HCRTR1HCRTR2KDM4ELMNA | |
| SCHEMBL4291196 | 0.85 | KDM4E (0.45) | HCRTR1HCRTR2KDM4ELMNA | |
| SCHEMBL4290199 | 0.85 | HCRTR1 (0.41) | HCRTR1HCRTR2KDM4E | |
| SCHEMBL4286026 | 0.84 | HPGD (0.49) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CPS1 2464/4885HCRTR1 3147/4885HCRTR2 3136/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CPS1 2464/4885HCRTR1 3147/4885HCRTR2 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.